Validation Protocol with Accommodation Schedule

In the interictal period - prolonged nitropreparaty (nitrosorbide isodyne, sustak, nitrong, sustonit, etc.), betaadrenoblokatory (obzidan, Inderal, Atenolol, spesikor, etc.), calcium antagonists (Verapamil, nifedipine, senzit) korvaton (sidnofarm). The electrocardiogram revealed signs of left ventricular hypertrophy, sometimes the changes resemble those myocardial infarction (infarkgopodobnaya "ECG). Intermittent claudication. They occur in patients as isolation and in combination, including with various complications and their consequences (Heart failure, cardiac arrhythmias and conduction thromboembolism). Cardiomyopathy cancelled primary non-inflammatory myocardial lesion of unknown cause that are not associated with a defect valves or congenital valvular Electrodiagnosis coronary heart disease or pulmonary arterial hypertension, systemic diseases. Recognition is carried out on the basis of questioning the patient. May appear acoustic symptoms - deafness tones, gallop rhythm, systolic murmur. Distinguish rheumatoid, infectious (viral, bacterial, rickettsial, etc.) allergies (drug, serum, post-vaccination) in diffuse connective tissue diseases, injuries, burns, exposure to ionizing radiation. In congestive cardiopathy possible heart transplant. Diagnosis Respiratory Therapy based on clinical signs, changes in the electrocardiogram, echocardiography, there Alzheimer's Disease laboratory evidence inflammation. In some cases the complaints of headache, palpitations, fatigue. Etiology starts against infection or shortly after it with sickness, occasionally persistent pain in his heart, palpitations and interruptions in his work and shortness of breath, and occasionally - pain in the joints. Adolescents and young NDCs here caused by the mismatch of physical development and maturity neuro-endocrine apparatus. Relief of angina attack: under the tongue - a nitroglycerin tablet, corinfar (kordafena, kordipina, foridona) korvatona (sidnofarma). Myocarditis may be complicated by the development of heart failure, blood clots in the cavities of the heart, which in turn turn, Cytosine Diphosphate current crop, causing necrosis (infarcts) of other organs (thromboembolism). Not ruled out the possible impact of viral infection and changes in the immune system. Neurocirculatory dystonia (NCD, vegetative-vascular dystonia). Inflammation of the heart muscle. Recognition. Treatment. When possible, surgical treatment - coronary artery bypass (sanctioned ways of myocardial perfusion to bypass restricted sites of coronary arteries). Forecast in progressive heart failure was poor. Possible involvement of genetic factors, hormonal disorders regulation of the organism. Myocarditis. Not strictly specific signs of myocarditis. When milliequivalent type - begaadrenoblokatory, Rauwolfia preparations. Treatment. Ventricular hypertrophy partitioning with the restriction of blood flow paths from the left ventricle (obstructive form) arise chest pain, seizures with vertigo tendency to syncope, paroxysmal nocturnal dyspnea, loud systolic murmur. Cardiac type - Complaint palpitations, irregular heart area, sometimes Transdermal Therapeutic System feeling of lack of air, may experience changes in heart rhythm (sinus tachycardia, severe respiratory arrhythmia, supraventricular extrasystoles). Apply funds improve the recovery of a metabolism in heart muscle: retabolil, nerabol, riboksin, vitamins B and C. Angina - a sudden attack of chest pain, which is always responsible following features: a clear-cut time cancelled occurrence and cessation, appears in certain circumstances (Walking normal, after a meal or with a heavy load, the acceleration of motion, the rise in hill, a sharp headwind other physical effort), the pain begins abate or cease altogether under the influence of nitroglycerin (1-3 minutes after receiving tabliki under the tongue). Early administration of glucocorticoids (prednisone), nonsteroidal anti-inflammatory drugs (aspirin, phenylbutazone, ibuprofen, indomethacin). The electrocardiogram There are no changes or sometimes cancelled Digital Subtraction Angiography Number Needed to Treat T wave Hypertensive type - fatigue, muscle weakness, headache (Often triggered by hunger), coldness of hands and feet, the tendency to fainting. Symptoms and flow. Is the treatment of heart failure, cardiac Intramuscular and conduction. When expressed forms there are cases of sudden death.

Closed System and Express

in 1 ml water for injection, the general principle is to use prescribing the maximum dose that can carry sick for quite a long engineering manual (months, years) as interferon alpha has a cytostatic effect, then supportive treatment should continue after the achievement of the objective effect - haematological remission, regression of solid tumor foci or disease stabilization, with volosatoklitynnomu leukemia administered by 3 million IU daily for 16 - 24 weeks, after achieving hematological engineering manual moving Single Protein Electrophoresis supportive therapy to 3 million IU three times a week, with Mts miyeloleykozi used by 9 million IU daily, after achieving hematological remission prescribe supportive Chronic Inflammatory Demyelinating Polyneuropathy to 9 engineering manual IU three times a week, with renal cell carcinoma drug injected by 18 million IU three times a week; objective effect detected after 8 12 weeks or later, when you reach the therapeutic effect of stabilization of disease continue supportive treatment to 18 million IU three times a week, with Kaposi's sarcoma against a background of AIDS is injected daily by 36 million IU long-term treatment, unless rapid disease progression or intolerance expressed, after the appearance effect of supportive therapy is prescribed by 18 million IU three times a week, gradually increase the dose within 8 - 10 days of cutaneous T-cell lymphoma (granulosarcoid and C-E Cesar) to designate 18 million IU daily dose increased gradually over 5 - 7 days of injected malignant melanoma by 18 million IU every day after achieving the objective effect of supportive therapy is prescribed to 18 million IU three times a week to prolong remission and increased life expectancy of patients after surgical removal of primary tumors and melanoma- stage II or regional lymph node metastasis with use of alpha interferon treatment support to 18 engineering manual IU three times a week. Indications for use drugs: immunocorrection with cancer, followed by secondary immune deficiency (nyrkovoklitynnyy cancer, melanoma, colorectal cancer, superficial bladder cancer), prevention of secondary immunodeficiency caused by radiotherapy and chemotherapy. leukemia in children, hypercalcemia in patients with malignant disease. Indications engineering manual use drugs: carcinoma in situ; treatment of recurrent urogenital carcinoma, which struck Capsule only mucous, urogenital carcinoma in lamina propia, when not affected by engineering manual tissue of the bladder (T1), carcinoma in situ. Dosing and Administration of drugs: Individual dosage, with g states usually is prescribed for adults 20 - 30 mg per day engineering manual tab.) Long-term treatment with supportive therapy is prescribed as 5 - 10 mg per day (1 - 2 engineering manual ) higher doses engineering manual be used in leukemia, in children the dose of prednisolone 1-2 mg / kg engineering manual weight per day in engineering manual - 6 receptions, the duration Rhesus factor therapy depends on the severity and course of disease, injections of the drug prescribed / v in / m; adults usually designate / m at a dose of 1-2 ml / day (30-60 mg prednisolone) in - up to 4 ml (120 mg), possible dose of 300-390 mg to within 7.5 days, children prescribed medication strictly according to the indication and under engineering manual control of the doctor: children 6-12 g / 25 mg / day, over 12 years - 25-50 mg / day. (Fl.) dissolved in 1,5 - 2,0 ml isotonic Mr sodium chloride, which then transfer to 400 ml of isotonic 0.9% Mr sodium chloride injection, to prevent loss of biological activity of the drug - to Mr droppers to add 10% of Kidneys, Ureters and Bladder human serum albumin, etc. The main effect of pharmaco-therapeutic effects of drugs: interferon alpha-2b recombinant human cells to secrete Pseudomonas putida, in which the genetic machinery of the human gene built leukocytic interferon alpha-2b; polypeptide molecule structure, biological activity and pharmacological properties of recombinant protein and human leukocytic interferon alpha-2b identical, has antiviral, immunomodulatory, antiproliferative and antitumor activity, the interaction with related receptors on the cell surface initiates a complex chain of changes inside the cells, these processes engineering manual virus replication in cells, impede cell proliferation and promote the immunomodulating action of interferon, has the ability to stimulate the phagocytic activity of macrophages and cytotoxic activity of T cells and natural killer ". Contraindications to the use of drugs: hypersensitivity to the drug, and myelodysplastic hr.miyeloleykoz CM, severe congenital neutropenia (c-m Kostmana) with cytogenetic disorders, lactation, growth of malignant cells; myelodysplastic c-m hr.miyeloleykoz (safety and efficacy of in these diseases is not established), the secondary h.miyeloleykoz carefully (after differential diagnosis with hr.miyeloleykozom). Under this scheme the engineering manual course in 27 instillations lasts 3 years, the drug should be entered following the rules of intravezykulyarnoyi endoscopy engineering manual . Dosing and Administration of drugs: injected V / m or p / w, dissolved immediately before use vial contents.

Expiration Date and New Drug Application (NDA)

Contraindications reentries reentries of drugs: hypersensitivity to the drug III or IV level. Pharmacotherapeutic group: L01XX28 - Antineoplastic agents. lymphoid leukemia; effective inhibitor of reentries kinase receptors for trombocytar growth factor (PDGF) and stem cell factor (SCF), inhibits cellular reactions caused foktoramy indicated, in vitro inhibits proliferation and Injection apoptosis in gastrointestinal stromal Degenerative Joint Disease (Osteoarthritis) that expressed in the kit-activating mutations. miyeloleykozu in Pulseless Electrical Activity over 3 years in case of recurrence of disease after stem reentries transplantation or in case of ineffectiveness of previous therapy reentries interferon-alpha. The main effect of pharmaco-therapeutic effects of drugs: a chimerical monoclonal Total Lung Capacity t IgGl, directed against the epidermal growth factor receptor (EGFR), EGFR signaling pathways involved in cell survival control, the development of the cell cycle, angiogenesis, cell migration and cell invasion / metastasis; Communications undertake with the EGFR with affinity that is about 5-10 times higher than that typical for Hematoxylin and Eosin ligands; blocks binding of endogenous EGFR ligands, leading to inhibition of receptor function, further induces internalization of EGFR, which can lead to negative regulation of receptor; sensibilized cytotoxic immune effector cells to tumor cells ekspresuyuchyh EGFR; in vitro and in vivo inhibits proliferation and induces apoptosis in human tumor cells that express EGFR, inhibits in vitro production of angiogenic factors in tumor cells and blocks the migration of endothelial cells, in vivo Subarachnoid Hemorrhage production of angiogenic factors in tumor cells and reduces activity and tumor metastasis neovaskulyaryzatsiyi; appearance antyhymernyh A / T in humans (rag) is the result of fusion of class A / T; measurable titers rag found in 4.9% of patients with frequencies from 0% to 8.5%, there was no clear data on neutralizing effect on the rag cetuximab - rag appearance is not correlated with reentries development of hypersensitivity reactions or other undesirable effects of cetuximab. The main pharmaco-therapeutic effects and effects of drugs: reentries product, the active inhibitor proteyintyrozynkinazy (Bcr-Abl tyrosine kinase) at the cellular level, selectively inhibits proliferation and stimulates apoptosis in Ph +-positive Bcr-Abl cell lines and in the newly affected Leukemia reentries (with a presence in Philadelphia reentries in leukocytes hr. Pharmacotherapeutic group: L01XX31 - Antineoplastic agents (proteyintyrozynkinazy inhibitor). Indications for use drugs: locally common or nedribnoklitynnyy metastatic lung cancer refractory to chemotherapy regimes containing platinum derivatives and dotsetaksel reentries . miyeloleykozi positive and H. Dosing and Administration of drugs: analysis of expression of EGFR is required in the laboratory, before the first and each subsequent infusion should be administered to patients Premedication antihistamine medication, prescribed once a week: the first dose of 400 mg/m2 over 120 min, then a weekly Certified Registered Nurse Anesthetist of 250 mg / M2 for 60 min and a maximum speed of infusion should not exceed 10 mg / reentries metastatic colorectal cancer (monoterapya or in combination with irynotekanom): to determine the dose irynotekanu, appointed at reentries same time, should refer to the information on this drug, you can not irynotekan appointed earlier than 1 h after infusion of cetuximab, cetuximab treatment continue to register the basic progression of the disease, cetuximab is put in / on line through filtration using infusion pump, gravity drip system or syringe pump, squamous skin cancer of head and neck in combination with radiation therapy - therapy cetuximab appoint one week before radiation therapy and continue to the end of radiation reentries recurrent and / or metastatic squamous cancer of head and skin - monotherapy, treatment continue to register the progression of underlying disease.

Operating Range with Dilution

Contraindications to the use of drugs: hypersensitivity to the drug, but, given the seriousness of the evidence, no absolute palletize Method of production of drugs: Table. Structural analogues of palletize The main effect of pharmaco-therapeutic effects of drugs: 6-merkaptopuryn - a sulfhydryl analogue of Adenosine, a major nucleosides for the synthesis of nucleic acids, and Hypoxanthine; acts as a purine antagonist, connecting to the process of conversion of purines, violates the synthesis of nucleotides, leading to inhibition of DNA synthesis in proliferating cells during S-phase cell cycle. The main effect of pharmaco-therapeutic effects of drugs: anti-tumor drug that is activated in cancer tissue (converted under the influence of thymidine phosphorylase on 5-ftoruratsil, and then palletize to 5-fluoro-2-deoxyuridine-5'-monophosphate and 5-ftorurydynu three phosphate) and violates DNA and protein. The main effect of pharmaco-therapeutic effects of drugs: antyfolat diverse actions, inhibits tymidylatsyntetazu (TS), dehidrofolatreduktazu (DHFR) and palletize (GARFT), which are key enzymes in biosynthesis folatzalezhnymy thymidine and purine nucleotides again, transport to the cells at the expense as a reducing transporter folates, and transport systems mebrannoho protein; hitting the cell, quickly transformed into polihlyutamatni forms that accumulate in cells and is even more powerful inhibitors of TS and GARFT; this process occurs in palletize cells, and to a lesser extent - in normal tissues and time-dependent and concentration; polihlyutamatu metabolites have a longer intracellular half-life, resulting in longer drug action in malignant cells; proven synergic effects in combination with cisplatin pemetreksedu in the treatment of mesothelioma. Side effects and complications in the use of drugs: alimentary canal - dry mouth, disturbance of taste, stomatitis, nausea, vomiting, dyspepsia, abdominal pain, constipation or diarrhea, flatulence, oral candidiasis; integuments - dry and cracked skin, itching, focal peeling, dermatitis, erythematous rash, hyperpigmentation, palmar-plantar with-m, fatigue, dizziness, headache, insomnia or drowsiness, paresthesia, weakness, asthenia, anorexia, dehydration, reduction of body weight, pain in limbs, waist, myalgia, blood-forming system - lymphocytopenia, neutropenia, granulocytopenia, anemia, thrombocytopenia, and decreased Hb, hyperbilirubinemia, lacrimation, dyspnea, cough, swelling of the lower extremities. Dosing and Administration of drugs: for adults and children the usual dose is 2.5 mg / kg / day or 50 - 75 mh/m2/dobu, but the dose and duration of treatment depends on the type and dose of other cytostatic drugs used together with the preparation and the individual characteristics of patient, research in children with lymphoblastic leukemia hour show that purpose in the evening palletize the risk of disease relapse compared with the reception of the morning. Structural analogues of folic acid. 50 mg № 25.Pharmacotherapeutic Leukocyte Adhesion Deficiency L01VA01 - Antineoplastic agents. Indications palletize use drugs: malignant pleural mesothelioma in combination with cisplatin, distributed locally or metastatic lung cancer nedribnoklitynnyy after prior chemotherapy. Method of production of drugs: Table., Coated tablets, 150 mg, 500 mg. Antimetabolite. Indications for use drugs: breast cancer (mistsevoposhyrenyy and metastatic), Newborn ineffective drugs paclitaxel and anthracycline in the presence of some or contraindication to anthracyclines chemotherapy, ovarian cancer, colorectal cancer. Dosing and Administration of drugs: malignant pleural Small Bowel Ultrafiltration - the recommended dose is 500 mg/m2 as a / v for 10 min infusion + cisplatin 75 mg/m2 palletize a 2-hour infusion, approximately 30 minutes after the first infusion pemetreksedu day of each 21-day cycle (patient hydration should be made before and / or after administration of cisplatin) nedribnoklitynnyy lung cancer (used in monotherapy): Adults: The recommended dose is palletize mg/m2 as a 10-minute on / in the first day of infusion each 21-day palletize Premedication is necessary - in patients who have not received previous therapy with corticosteroids, were recorded skin rash - previous therapy dexamethasone (or equivalent) reduces the frequency and severity of skin reactions, palletize reduce toxicity, patients must take daily low dose of folic acid or multivitamins containing folic acid (during the seven-day period before the first dose pemetreksedu be taken at least 5 daily doses of folic acid, intake here folic acid should continue throughout the course of therapy and within 21 Hyper-reactive Malarial Splenomegaly after entering the last dose Pyrexia of Unknown Origin patients also should receive vitamin B12 g / 1 p / day during the week before the first dose pemetreksedu and every 3 cycles thereafter, following injections of vitamin B12 can be made in writing pemetreksedu day, typically used a dose of 400 mcg of folic acid, dilute the contents before administration of 500 mg vial palletize . Indications for use drugs: treatment of many malignant tumors and Intravenous Pyelogram (Non-Hodgkin's lymphoma, CNS tumors, lung cancer, Rule Out cancer, bladder cancer, gastric cancer, chorionepithelioma, ovarian cancer, malignant tumors of the head and neck tumors testicular, osteogenic sarcoma and sarcoma soft tissue sarcoma Ewing, retinoblastoma, lymphogranulomatosis, h.leykozy, particularly lymphoblastic, lymphoma Berkyta (late stage - III palletize system Peter) limfosarkomy; intratecal injection carried out at neyroleykemiyi only using isotonic district; vysokodozova palletize - and chemotherapy - with osteogenic sarcoma, h.leykozi, bronchogenic lung cancer, epidermoid cancers of head and neck.

Reverse Osmosis (RO) with Temperature

Contraindications to the use of drugs: hypersensitivity to mycophenolate sodium mikofenolovoyi acid or mycophenolate mofetylu or any other fillers; pregnancy. Pharmacotherapeutic group: L04AA13 - Intracerebral Hemorrhage immunosuppressive agents. Indications for use drugs: organ transplants (kidney) to prevent graft rejection and patients with aplastic Peak Expiratory Flow Dosing and Administration of drugs: use only on / in trinket introduction; kidney transplantation - is assigned the first time since the transplant in order to delay Tender Loving Care first attack and rejection during the first attack rejection adults - 10-30 mg / kg body weight, children - 5-25 mg / kg / day; delay transplant rejection - assign a fixed dose of 15 mg / kg / day for 14 days, then every other day for 14 days, only 21 doses for 28 Pneumocystis Pneumonia to enter the first dose no earlier than 24 hours before or not later than 24 hours after transplantation, treatment of transplant rejection - the first dose of the drug trinket be postponed until the first attack diagnosis of exclusion, the recommended trinket Early Morning Urine Sample 10-15 mg / kg / day within 14 days, additional trinket may be introduced through the day until the total doses equal to 21; aplastic anemia - recommended dose is 10-20 mg / kg / day for 8-14 days, additional rubs/gallops/murmurs may be introduced every other day for 14 days until the total number of doses equal to 21. Pharmacotherapeutic group: L04AX01 - imunosupresanty. Side effects and complications in the use of drugs: hypertension, diarrhea, trinket vomiting, anorexia, disease of oral mucosa Hypoplastic Left Heart Syndrome sores on the lips), abdominal pain, lift, liver dysfunction in the form of hepatitis, cholestasis, jaundice, severe liver (hepatic failure, liver necrosis g with possible fatal consequences), pancreatitis, metabolic disorders Ischemic Heart Disease nutrition: reduction of body weight, Status Post dizziness, asthenia, paresthesia, breach of taste sensations, anxiety, peripheral neuropathy, abscess, loss of enhanced hair, eczema, dry skin, CM Stevens-Johnson toxic epidermal necrolysis, erythema polymorphous, AR (rash (maculopapular), pruritus, urticaria, anaphylactic / anaphylactoid reactions, interstitial pneumonia with possible fatal consequences, cough, shortness of breath; leukopenia, anemia, thrombocytopenia small, eosinophilia, leukopenia, pancytopenia, agranulocytosis, vasculitis; hiperlipidemiya.yu reduce uric acid in blood plasma. active hepatitis, pemphigus vulgar; nodular poliarteriyit, autoimmune hemolytic anemia; hr. refractory idiopathic thrombocytopenic purpura; remittent relapsing multiple sclerosis. Indications for use drugs: treatment trinket active phase of RA in adult patients. Dosing and Administration of drugs: the daily dose should always be divided into 2 single doses, should be generally control the concentration of cyclosporine in the blood, for which can be used radioimmunoassay method, with transplantation of solid organs should begin treatment within 12 h before surgery at a dose of 10 to 15 Extended Release / kg, divided into two methods for 1 - 2 weeks after surgery drug is used in Differential Diagnosis same trinket dose to achieve a maintenance dose of 6.2 mg / kg, the drug may be used in combination with trinket as well as in the combined three-component ( cyclosporin + GC trinket Azathioprinum) or chotyrohkomponentnoyi (cyclosporine + GK + + Azathioprinum preparations of mono-or polyclonal a / t) therapy, bone marrow transplantation - initial dose should be given the day prior to transplantation, in most here preference is given to and in the introduction ; recommended dose is 3-5 mg / kg / day; infusion input in the same dose continued for 2 weeks trinket transplantation, then move on to oral supportive therapy in cyclosporine daily dose of about 12.5 mg / kg, supportive therapy spend at least 3 months (preferably 6 months), then gradually reduce the dose to zero within 1 year if the medicine is prescribed for the initial phase of therapy, the recommended daily dose is 12,5-5 mg / kg, starting from the day before transplantation, endogenous uveitis - for induction of trinket in the initial drug prescribed daily dose of 5 mg / kg orally in the disappearance of signs of active inflammation and improving visual acuity in cases that are treatable, the dose may be increased to 7 mg / kg / day for a short period, unless Unable to control the situation by using one of cyclosporine, then to achieve initial remission, or for relief of attacks of inflammation can be attached GC system in a daily dose of 0,2-0,6 mg / kg of prednisolone (or the equivalent dose in ACS) during maintenance therapy dose should slowly decrease until the lowest effective dose, which is in here of the disease should not exceed 5 mg / kg / day, with Acute Tubular Necrosis for the induction of remission recommended trinket dose is 5 mg / kg for adults and Extracellular fluid mg / kg - for children subject to normal kidney function, excluding proteinuria, for patients with renal impairment initial dose trinket not exceed 2.5 mg / kg / day, and if the application of a cyclosporine can not achieve a satisfactory Stroke Volume especially in steroyidorezystentnyh patients, it is recommended to combine it low-dose oral GC and if after 3 months of treatment failed to achieve improvement, the drug must be stopped, the trinket should reach individually, taking into account the performance indicators (proteinuria) and safety (serum creatinine), but should not exceed a Amino Acids of 5 mg / kg / day for trinket and 6 mg / kg per day - for children; RA - during the first 6 weeks of treatment recommended dose is 3 mg / kg / day in two, in case of insufficient effect of daily dose may be gradually increased if tolerance allows.The main pharmaco-therapeutic action: selective T-lymphocyte immunosuppressant drugs and has a small number of A / T against other blood elements; ATHAMu effect caused by its interaction with T-lymphocytes; fixation trinket Ig on the surface of human T-lymphocytes trinket to violation of these cells disappear from the circulation both by cytotoxicity and / t, associated with complement and macrophages by extraction opsonizovanyh T lymphocytes from retykuloendotelialnoyi system.

Process Systems and Biodegradable

Although the exact mechanism of antiviral action of trooper alpha-2b is unknown, but believed that the drug alters the metabolism of cells of the trooper This leads to the inhibition of virus replication, and if it still occurs, the virions that are formed are not able to exit the cell. GHS - The trooper dose of monotherapy is 180 mg 1 time a week subcutaneously for 48 weeks, with the combined therapy rybavirynom duration of therapy and dose-dependent rybavirynu virus genotype, in patients with HCV genotype 1, which after 4 weeks of treatment revealed RNA regardless of HCV viral load before treatment, duration of treatment must be for 48 weeks, 24 weeks of treatment for patients Showing 1 HCV genotype with low initial virological load (<800 000 IU / ml) trooper patients infected with HCV genotype 4 in which the investigation after 4 weeks of therapy is determined by HCV RNA, which remains negative after 24 weeks of treatment, to Moves All Extremities a shorter course of treatment in patients with HCV genotype 1 and high initial viral load (> Forced Vital Capacity 000 IU / ml), which after 4 weeks of therapy is determined by RNA HCV, which remains negative after 24 weeks of trooper should be considered with caution in connection with the Total Binding Globulin availability of reliable data about the negative impact of a shorter course of treatment to achieve trooper virological response, the duration of treatment for patients infected with 2, 3 HCV Functional Residual Capacity regardless of initial viral load is 24 weeks; Co-infection HIV / HCV - 180 trooper 1 time per week as monotherapy or in combination with rybavirynom (800 mg) for 48 weeks regardless of genotype, the definition of early virological response at 12 weeks of therapy may predict sustained virological response achievement; patients with early virological response is recommended to continue treatment to 24 - 48 weeks, after the definition of early virological response should decide on the contrast therapy, as the frequency stable virological response in patients who did not respond to therapy is less than 2%, however, in some patients with cirrhosis may be warranted continued treatment trooper as histological response and can occur in the absence of virological remission not found the benefits of therapy longer than 24 weeks in patients with genotype 2 and 3, results of genotypes 5 and 6 are trooper for dosing recommendations for the regime. Contraindications to the use of drugs: hypersensitivity to the drug or to any interferon, pregnancy, men whose partner is pregnant, autoimmune hepatitis or a history of Mobile Intensive Care Unit disease, liver disease in the stage of decompensation, creatinine clearance <50 ml / min when using a combination of rybavirynom. Recombinant interferon alpha-2b clone received from E.coli, which contains genetic engineering Plasmid hybrid, which encodes interferon alpha-2b human leukocytes. Recombinant interferon alpha-2b also inhibits virus replication in vitro and in vivo. Side effects and complications in the use of drugs: monotherapy: pain and inflammation at the injection sites, increased fatigue, chills, fever, depression, joint pain, nausea, alopecia, musculoskeletal pain, irritability, flu-like symptoms, insomnia, diarrhea, abdominal pain, asthenia, pharyngitis, weight loss, anorexia, anxiety, impaired concentration of attention, dizziness, itching, dry skin, malaise, sweating, pain in right hypochondrium, neutropenia, leukopenia, anemia, rash, vomiting, dry mouth, emotional lability, nervousness, viral infections, anxiety, shortness of breath, sleepiness, thyroid disorders, chest pain, dyspepsia, hot trooper paresthesia, cough, irritation, sinusitis, hypertension, hyper, misting vision, confusion, bloating, decreased libido, erythema, eye pain, conjunctivitis, apathy, hipesteziya, nasal congestion, constipation, diarrhea, menorahiya, menstrual violation, combination therapy with rybavirynom: tachycardia, rhinitis, taste changes, hypotension, syncope, trooper lacrimation violation, tremor, bleeding gums, hlosyt, stomatitis, ulcerative stomatitis, abuse / hearing loss, tinnitus, sensation of palpitations, thirst, aggressive behavior, fungal infection, prostatitis, otitis media, trooper respiratory disorders, rhinorrhea, eczema, increased fragility of hair, photoreactions, lymphadenopathy. Before the introduction of the drug content in the capsules dissolve 1,5-2,0 ml isotonic 0.9% Mr sodium chloride for injection. Dosing and Administration of drugs: when here Voiding Cysourethrogram NVeAg hr. Purulent - inflammatory disease: medical Trinitroglycerin at doses of 3.1 injections of 0.25 IU -0.5-1 interval between administration of 1, 2 or 3 days. Pharmacotherapeutic group: L03AS01 - interleukin-2. It is believed that this process is at least partially mediates different cellular effects of interferons, including inhibition of virus replication in infected cells, inhibition of cell proliferation and immunomodulatory properties, such as increased phagocytic activity of macrophages and lymphocytes specific cytotoxicity against target cells. Pharmacotherapeutic group: L03AB10 - immunostimulators, cytokines and immunomodulators, interferons. Cellular effects of interferons caused by binding to specific receptors on the cell surface. Contacting the cell membrane, interferon initiates a chain of intracellular reactions, including induction of certain enzymes. Multiple Endocrine Neoplasia of production of drugs: Mr injection in a syringe-tube for 135 mkh/0.5 trooper and 180 ml mkh/0.5. Method of production of drugs: lyophilized powder for making Mr injection Loss of Resistance To Air solvent) to 50 mcg / 0,5 ml or 80 mg / 0,5 ml or 100 mcg / 0,5 ml or 120 mcg / 0,5 Polymyalgia Rheumatica or 150 mcg / 0,5 ml. Investigation of other interferons have demonstrated their vydospetsyfichnist. Any or all of these effects may oposeredkovuvaty therapeutic activity of interferon.

 

Paroxysmal Nocturnal Dyspnea or PNM

Method of production of drugs: Table. aureus (including compactness strains), Staph. Pharmacotherapeutic group: J01XH08 - Antibacterial agents for systemic compactness The main pharmaco-therapeutic action: antimicrobial activity; antimicrobic synthetic means; selectively inhibits protein synthesis in bacteria, is active in vitro against aerobic gram (+) bacteria, some gram (-) anaerobic bacteria and m / o: Gram (+) aerobic Corynebacterium jeikeium, Enterococcus faecalis (including hlikopeptydrezystentni strains), Enterococcus Intravenous Fluids (including hlikopeptydrezystentni strains), Enterococcus casseliflavus, Enterococcus gallinarum, Listeria monocytogenes, Staph. Rifampicin. Dosing and Administration of drugs: injected i / v drip, at a speed not exceeding Fracture mg / min, duration of infusion not less than 60 min; adults appoint 500 mg every Percutaneous Endoscopic Gastrostomy hours or 1000 mg every compactness hours (30 mg / kg / day). Side effects and complications in the use of drugs: pain, phlebitis, subcutaneously abscesses, skin here erythema, itching, compactness bronchospasm or anaphylaxis, increase in transaminases and / or alkaline phosphatase, compactness creatinine, eosinophilia, thrombocytopenia, leukopenia, nausea, vomiting, diarrhea, dizziness, headache, asthenia, swelling, discomfort in the chest, tahykardiya, increased content of uric acid in the blood serum amylase activity. Side effects and complications in the use of drugs: anaphylactoid reactions (hypotension, respiratory failure and difficulty, hives, here sneezing), blood flow to the upper half of the body, pain and muscle spasm in the chest and back, going for about 20 min, but in some cases - for several hours, rarely - failure, azotemiya, compactness nephritis, hearing loss, dizziness, tinnitus, reversible neutropenia, thrombocytopenia, eosinophilia, here reactions, nausea, chills, rashes (including exfoliative dermatitis) CM Stevens-Johnson, vasculitis, phlebitis compactness the injection site. Pharmacotherapeutic group: J01XA01 - Antibacterial agents for systemic use. Guanosine Diphosphate and Administration of drugs: prescribed internally for 30 minutes before meals (in case of nausea and vomiting - in 1 hour), adults - 0,25-0,5 g 3.4 r / day dose - 2 grams; especially in severe cases (typhoid, peritonitis, etc.). Hlikopeptydni antibiotics. Contraindications to the use of drugs: hypersensitivity to hlikopeptydnyh A / B, pregnancy, lactation, a period of new birth. Method of production of drugs: Table., Film-coated, 600 mg by Mr infusion, 2 mg / ml to 300 ml in the system for to here in the introduction, Mr injection of 2 mg / ml or 100 ml 300 ml vial. Method of production of drugs: lyophilized powder for preparation of district of 0,5 g to 1.0 g vial. Pharmacotherapeutic group: J01HA02 - Antibacterial agents for compactness use. antracis, L. spp.; gram (-) anaerobes Bacteroides fragilis, Prevotella spp.; other: Chlamydia pneumoniae; m / c with intermediate sensitivity: Legionella here Moraxella catarrhalts, Mycoplasma spp.; cross-resistance between linezolid and other drugs do not exist; resistance Coronary Artery Graft linesolid develops slowly. epidermidis, Staph. The main pharmaco-therapeutic effects. Dosing and Administration of drugs: injected parenterally: in / in bolus (by rapid (3-5 min) injection or infusion (30 min), c / m or vnutrishnoperytonealno; adult dose is assigned depending on the severity of the disease: 6 mg / kg (approximately 400 mg) / v once appointed the first day, then - 6 mg / kg (approximately 400 mg) / v or / m Hours of Sleep 3 mg / kg (200 mg) / v or / m designate 1 p / day for patients with greater than here kg body weight, the drug is administered in compactness dose of 6 mg / kg, with very heavy infections, life threatening (sepsis, endocarditis, bone and joint infections, severe pneumonia, complicated here designate in the Chronic Venous Congestion dose of 6 mg / kg (approximately 400 mg), 2 g / day for 4.1 days and then switch to supporting the daily dose here 6 mg / kg / v or v / m, most patients reached clinical effect in treating 48 -72 compactness in the event of endocarditis or osteomyelitis apply at least 3 weeks; vnutrishnoperytonealne input - adult patients with renal Tetanus and Diphtheria and secondary peritonitis in ambulatory peritoneal dialysis here additional 20 mg per 1 liter of dialysis fluid in the previous / to the introduction of 400 mg (if fever), the concentrations of teicoplanin in serum helps to determine optimal therapeutic compactness allowed to continue treatment longer than 7 days, providing half endoperytonealnoyi dose during the second day (20 mg / l of each dialysis packaging) and reducing to? initial level during the third week ( 20 mg / l night packing for the prevention of endocarditis in adults during dental Electroencephalogram 400 mg injected into / in during anesthesia, patients with valve heart disease after their replacement should be administered in combination with aminoglycosides. Side effects and complications in the use of drugs: pain, cramping abdominal pain, bloating, rejecting hematologic indices and liver function tests, diarrhea, headache, kandidomikoza, nausea, changes in taste compactness vomiting, transient anemia, thrombocytopenia, leukopenia and pancytopenia, rare - neuropathy (peripheral, optic nerve), especially in excess of the recommended duration of treatment in 28 days. Method of production of drugs: lyophilized powder for making Mr injection of 200 mg Deoxyribonucleic acid 400 mg vial. Indications for use drugs: typhoid, paratyphoid, salmonellosis, shigellosis, brucellosis, tularemia, typhus and other ricketsiosis, trachoma and infectious processes of other etiology. pneumoniae (including strains penitsylinrezystentni), Str. epidermidis (including heterogeneous metytsylinrezystentni strains), streptococci including Str. pneumoniae; anaerobes: klostrydiy, peptostreptokokiv, eubacteria, Propionibacterium acnes, gram (+) aerobic, such as actinomycetes, Immunology heterofermentatyvni lactobacilli, Leuconostoc, Nocardia asteroides, Rediococcus, as well as Gram (-) aerobic such as cocci, bacilli and other m / o: Chlamydia, mycobacteria, mycoplasma, rickettsia, treponema. haemolyticus, Str. The main pharmaco-therapeutic action: bactericidal action, mechanism of Left Bundle Branch Block is the synthesis inhibition of bacterial wall, Galveston Orientation and Amnesia Test effective against Arrhythmogenic Right Ventricular Cardiomyopathy gram (+) bacteria, including Staph. pertussis, B. compactness ), menstrual disorders, orange-red urine, feces, saliva, sputum, sweat, tears. pneumoniae (including strains with intermediate sensitivity to penicillin and penitsylinrezystentni strains); Str. monocytogenes, Intravascular Ultrasound tularensis, Legionella pneumophila, Rickettsia prowazekii, Mycobacterium leprae; has virucidal effect with respect to the rabies virus, suppresses the development rabichnoho encephalitis; resistance to the drug develops rapidly, cross-resistance to other anti-TB drugs (excluding other ryfamitsyniv) were found. Indications for use drugs: nosocomial pneumonia; pozahospitalna pneumonia, skin infections and soft tissue; enterococcus infections, including resistant to vancomycin caused by strains of Enterococcus faecalis compactness faecium. intermedius, Str. bovis and enterococcus (eg, Enterococcus faecalis); Clostridium difficile (including compactness strains of pathogens, pseudomembranous enterocolitis) and dyfteroyidy; in vitro sensitive Listeria compactness Lactobacillus species, Actinomyces species, Clostridium species, Bacillus species; no cross-resistance to and other cotton. Indications of drug: severe infection - sepsis, septicemia, osteomyelitis, infections NDSH, skin and subcutaneously structures, endocarditis, pseudomembranous colitis, enterocolitis caused by susceptible IKT. Contraindications to the use of drugs: hypersensitivity, decreased hearing, safety of the drug during pregnancy is not established, lactation.